DLH (NasdaqCM:DLHC) Q4 2025 Earnings Call December 11, 2025 10:00 AM ET Company ParticipantsChris Witty - Head of Investor RelationsZach Parker - President and CEOKathryn Johnbull - CFOConference Call ParticipantsJoe Gomes - Senior Research AnalystOperatorGood day and welcome to the DLH Holdings Corp. Fiscal 2025 Fourth Quarter Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. A ...

USANA Health Sciences Conference Summary Company Overview - **Company Name**: USANA Health Sciences (NYSE: USNA) - **Founded**: 1992 as a spinoff of Gull Laboratories - **Business Model**: Manufactures, develops, and distributes high-quality science-based nutritional and personal care products focusing on long-term health and wellness [2][3] Key Business Segments - **Sales Channels**: - Direct sales (legacy business) - Direct-to-consumer (DTC) channel as part of diversification strategy [3][4] - **Geographic Distribution**: - Significant concentration in Greater China, with ongoing risks and opportunities [4] - Currently operates in 25 markets globally [5] Financial Highlights - **Active Customers**: - Total of 388,000 active customers as of Q3, with 43% being brand partners and 57% preferred customers [9] - **Manufacturing**: - 69% of products manufactured in-house, providing operational flexibility and quality control [11][33] - **Debt Status**: - No debt as of Q3 2024, with healthy free cash flow [26] Strategic Initiatives - **M&A Activity**: - Acquisition of Hiya Health in December 2024, focusing on children's health and wellness [20][21] - Hiya's growth strategies include expanding product portfolio and distribution channels [25][37] - **Diversification Strategy**: - Broadened distribution channels and geographic presence through acquisitions [19][29] Market Trends and Opportunities - **Health Awareness**: - Increased consumer awareness post-COVID regarding health management, creating opportunities for growth in nutritional products [18] - **Direct Selling Model**: - Emphasis on empowering independent business owners to market products, despite facing some pressure [7][38] Challenges and Future Outlook - **Direct Selling Business**: - Experiencing downward trends in top-line growth, actively addressing through product innovation and enhanced brand storytelling [38] - **International Expansion**: - Continued focus on expanding into new markets, particularly India, and leveraging existing international presence [29][30] Additional Insights - **Product Development**: - Commitment to science-based product formulation, leveraging clinical studies and research [12][33] - **Marketing Strategy**: - Utilizes testimonials from athletes to enhance brand credibility and consumer trust [13] - **Sustainability Initiatives**: - Focus on clean, transparent ingredients and engaging marketing strategies to foster customer loyalty [23][24] This summary encapsulates the key points discussed during the USANA Health Sciences conference, highlighting the company's strategic direction, market positioning, and future growth opportunities.

Summary of ABS-201 Conference Call Company and Industry Overview - **Company**: Absci - **Industry**: Biopharmaceuticals, specifically focusing on treatments for androgenetic alopecia (AGA) Key Points and Arguments 1. **Mission and Focus**: Absci aims to leverage generative AI to develop better biologics for patients with unmet medical needs, particularly in the area of hair loss, which is often dismissed as cosmetic but has significant psychosocial impacts on patients [1][2][13] 2. **ABS-201 Overview**: ABS-201 is positioned as a potentially paradigm-changing therapeutic for AGA, utilizing a novel mechanism involving the prolactin receptor pathway, which is believed to offer a differentiated and best-in-class profile [2][3][18] 3. **Patient Impact**: The psychosocial effects of hair loss are emphasized, with testimonials highlighting the emotional toll and identity issues faced by individuals suffering from AGA [5][7][12][13] 4. **Clinical Trial Design**: The upcoming phase 1/2a clinical trial for ABS-201 will assess safety, tolerability, and efficacy, with an interim efficacy readout expected in the second half of 2026 [43][45] 5. **Scientific Validation**: The mechanism of action for ABS-201 involves blocking the prolactin receptor, which has shown promising results in preclinical studies, including significant hair growth and repigmentation in non-human primates [22][23][40] 6. **Market Opportunity**: There is a significant commercial opportunity in the hair loss treatment market, especially as awareness and demand for effective treatments grow among both men and women [2][15][17][26] Additional Important Content 1. **Expert Insights**: Various experts, including dermatologists and researchers, provided insights into the biological mechanisms of hair loss and the potential of ABS-201 to address these issues [19][29][50] 2. **Historical Context**: The discussion included a historical perspective on hair loss treatments and the evolution of understanding regarding the role of hormones like prolactin in hair growth [30][51] 3. **Regulatory Considerations**: The trial design includes rigorous endpoints and assessments to ensure that the results are meaningful and can support regulatory approval [44][56] 4. **Patient-Centric Approach**: Emphasis on the importance of patient-reported outcomes alongside clinical measurements to gauge the true impact of treatment on quality of life [44][45] This summary encapsulates the critical aspects of the ABS-201 conference call, highlighting the innovative approach of Absci in addressing a significant medical need through advanced biopharmaceutical development.

Financial Data and Key Metrics Changes - The company reported revenue of $81.2 million in Q4 2025, down from $96.4 million in the prior year, primarily due to contract transitions and government efficiency initiatives [14][15] - EBITDA for Q4 was $6.6 million, compared to $10.7 million in the previous year, reflecting lower revenue and pressure on gross margins [15][16] - For the full year, revenue totaled $344.5 million, with EBITDA at $34 million, approximately 10% of revenue, and free cash flow of $23 million [16][17] - The company reduced debt by $10.7 million during the quarter, ending the fiscal year with $131.6 million in debt, a total reduction of $23 million over the year [17][18] Business Line Data and Key Metrics Changes - The revenue decline was attributed to approximately $11 million from small business set-aside conversions, with $7.5 million related to transitioned CMOP locations and $2.9 million from contract unbundling [14][15] - The company has been awarded a sole-source IDIQ contract to continue providing pharmacy and logistics services, with task orders already received [15] Market Data and Key Metrics Changes - The company achieved cybersecurity maturity model level two certification, enhancing its competitive position in the market [7] - The company is optimistic about growth opportunities in its addressable market as it transitions into a leading technology and engineering solutions provider [6][9] Company Strategy and Development Direction - The company is focused on digital transformation, cybersecurity, systems engineering, and scientific research as core capability pillars [9][10] - Investment in proprietary tools like DLH Cyclone, an AI/ML-powered data science engine, is expected to drive organic growth and enhance competitive differentiation [10][12] - The company aims to return to low double-digit organic growth in the future, leveraging its strategic differentiators and top talent [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth opportunities despite challenges faced during the fiscal year, emphasizing the importance of diversification and innovation [17][30] - The company anticipates returning to historical growth and EBITDA margins, with new contract awards expected in early 2026 [28][30] Other Important Information - The company has made all mandatory term debt payments through September 30, 2026, a year ahead of schedule [18] - The pipeline of qualified opportunities is strong, exceeding $3 billion, indicating healthy financial growth prospects [31] Q&A Session Summary Question: Status of the Head Start program and potential protest - The company did not participate in the protest regarding the Head Start program transition to small business set-asides, acknowledging the shift in strategy by the government [22] Question: Timeline for remaining CMOP awards - The company is not bidding on remaining CMOP contracts but is supporting a small business partner, with decisions expected in the coming quarter or two [24][25] Question: Expected return to historical growth and EBITDA margins - Management anticipates new business opportunities within the VA and other sectors to positively impact margins, with awards expected in early 2026 [28][30] Question: Current size of the pipeline - The company reported a pipeline exceeding $3 billion, indicating strong growth potential over the next 24 months [31]

Financial Data and Key Metrics Changes - In Q3 2025, revenues reached $41.4 million, a 25% increase compared to the same period in 2024 [4][15] - Operating income for Q3 2025 was $10.3 million, marking a 72% increase year-on-year and a 23% increase from Q2 2025 [4][5] - Net income for Q3 2025 was $11 million, slightly lower than Q2 2025 due to declines in time deposit income and minor foreign exchange losses [5] - EBITDA for Q3 2025 was $18 million, while net income for the nine months of 2025 totaled $35 million [17][18] - The company ended the nine-month period with approximately $100 million in cash, a decrease due to the $129 million payment for the acquisition of seven dry bulk ships [5][18] Business Line Data and Key Metrics Changes - The integration of seven dry bulk ships led to a 36.1% increase in fleet calendar days quarter-on-quarter [3] - Fleet operational utilization improved to about 89% in Q3 2025, compared to 66% in the same quarter last year [3] - Daily net revenue from dry bulk vessels increased by about 23% in Q3 2025 compared to Q3 2024 [15] - Time charter coverage increased to 75% in Q3 2025 from 27% in Q3 2024 [16] Market Data and Key Metrics Changes - Suezmax tanker rates increased to approximately $55,000 per day in Q3 2025, with recent rates nearing $70,000 per day [16] - Daily rates for Supramaxes rose from $10,000 to $16,000, while Kamsarmax rates increased from $12,000 to $15,000 [10] - The dry bulk market saw a significant rise in coal trade and grain volumes, with expectations for continued growth in 2026 [13] Company Strategy and Development Direction - The company aims to expand its fleet to between 25 and 30 ships, supported by a recent capital raise of $60 million [6] - The focus remains on enhancing revenue, profits, and asset utilization through fleet expansion [6][20] - The company maintains a debt-free balance sheet and a strong cash base, which supports its operational and capital commitments [7][22] Management Comments on Operating Environment and Future Outlook - The management expressed optimism about the tanker and dry bulk markets, noting solid market rates and favorable conditions [6][21] - Geopolitical tensions and their potential impact on the market were acknowledged as a concern for the future [19] - The company expects a favorable prospect for Q4 2025, driven by strong operating performance and market conditions [19][22] Other Important Information - The company incurred negligible dry docking costs in Q3 2025, but a heavy dry docking schedule is anticipated for 2026 [17] - The fleet book value increased to $343 million, reflecting a 65% expansion in the asset base within nine months [18] Summary of Q&A Session - There was no question-and-answer session at the end of the conference call, as all participants were in a listen-only mode [1]

Financial Data and Key Metrics Changes - In Q3 2025, revenues reached $41.4 million, a 25% increase compared to the same period in 2024 [4][15] - Operating income for Q3 2025 was $10.3 million, marking a 72% increase year-over-year and a 23% increase from Q2 2025 [4][5] - Net income for Q3 2025 was $11 million, slightly lower than Q2 2025 due to declines in time deposit income and minor foreign exchange losses [5] - EBITDA for Q3 2025 was $18 million, while net income for the nine months of 2025 was $35 million [17][18] - The company ended the nine-month period with approximately $100 million in cash, a decrease due to a $129 million payment for seven dry bulk ships [5][18] Business Line Data and Key Metrics Changes - The fleet operational utilization in Q3 2025 was about 89%, significantly improved from 66% in the same quarter last year [3] - The daily net revenue from dry bulk vessels increased by about 23% in Q3 2025 compared to Q3 2024 [15] - Time charter coverage increased to 75% in Q3 2025 from 27% in Q3 2024, reflecting a shift in fleet employment strategy [16] Market Data and Key Metrics Changes - Market rates for Suezmax tankers increased to approximately $55,000 per day in Q3 2025, with rates now close to $70,000 per day [16][21] - Daily rates for Supramaxes rose from $10,000 to $16,000, while Kamsarmaxes increased from $12,000 to $15,000 [10][13] - The dry bulk market saw a significant rise in coal trade and grain volumes, with expectations for continued growth in 2026 [13] Company Strategy and Development Direction - The company aims to expand its fleet to between 25 and 30 ships, supported by a recent capital raise of $60 million [6][8] - The focus remains on enhancing revenue, profits, and asset utilization through fleet expansion and strategic management of vessel employment [6][20] - The company maintains a debt-free balance sheet and strong operating cash flow, positioning itself for better performance in the upcoming quarters [7][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the tanker and dry bulk markets, noting solid market conditions and potential for further rate increases [6][11] - Geopolitical tensions and their potential impact on the market were acknowledged as a concern, but the overall outlook for Q4 2025 remains favorable [19] - The company is focused on quality-built ships and aims to leverage its strong fundamentals for future growth [21] Other Important Information - The company incurred negligible dry docking costs in Q3 2025, but a heavy dry docking schedule is anticipated for 2026 [17] - The fleet book value increased to $343 million, reflecting a 65% expansion in the asset base within nine months [18] Summary of Q&A Session - There was no question-and-answer session at the end of the conference call, as all participants were in a listen-only mode [1]

Summary of Artis Real Estate Investment Trust Extraordinary General Meeting Company Overview - **Company**: Artis Real Estate Investment Trust (OTCPK: ARES.F) - **Meeting Date**: December 11, 2025 - **Format**: Hybrid (in-person and virtual via Lumi Connect) Key Points and Arguments Meeting Structure and Procedures - The meeting was chaired by Liz Wigmore, a trustee and chair of the special committee [1] - Introduction of trustees and senior management team members present at the meeting [2] - The meeting required a quorum of at least 25% of issued and outstanding common and preferred units to proceed [4][5] - Voting procedures were outlined for both in-person and remote attendees, with ballots provided for registered unit holders [7][9] Special Resolutions - A special resolution was proposed to approve a statutory amendment and restated plan of arrangement involving Artis and RFA Capital Holdings Inc. [10][11] - The arrangement would result in the formation of a new company, RFA Financial Inc., with Artis REIT as a wholly owned subsidiary, and common unit holders would own 68% of RFA Financial Inc.'s common shares [11] - Separate votes were required for Series E and Series I preferred units, each needing at least two-thirds approval [6][18][21] Equity Incentive Plan - An ordinary resolution was presented for holders of common units to approve an equity incentive plan for the resulting issuer, which included a monetary limit on non-employee director participation [22][26] Voting Results - All resolutions were voted in favor by the necessary margins, concluding the formal business of the meeting [27] Additional Important Content - The meeting included a general question-and-answer session, allowing unit holders to engage with the Board and management [30] - Acknowledgment of the support from unit holders and partners was expressed, highlighting the importance of their engagement throughout the process [32][33] This summary captures the essential elements of the meeting, including the company involved, the key resolutions discussed, and the overall engagement with unit holders.

Financial Data and Key Metrics Changes - In Q3 2025, revenues reached $41.4 million, a 25% increase compared to the same period in 2024 [5][17] - Operating income for Q3 2025 was $10.3 million, marking a 72% increase year-over-year and a 23% increase from Q2 2025 [5][6] - Net income for Q3 2025 was $11 million, slightly lower than Q2 2025 due to declines in time deposit income and minor foreign exchange losses [6][20] - EBITDA for Q3 2025 was $18 million, while net income for the nine months of 2025 totaled $35 million [19][20] Business Line Data and Key Metrics Changes - The dry bulk segment saw a 23% increase in daily net revenue in Q3 2025 compared to Q3 2024 [17] - Time charter coverage increased to 75% in Q3 2025 from 27% in Q3 2024, reflecting a shift in fleet employment strategy [18] - The average daily operating expenses (OpEx) for the tanker fleet was around $7,200, while for the dry bulk fleet it was $5,600 [19] Market Data and Key Metrics Changes - Suezmax tanker rates increased to approximately $55,000 per day in Q3 2025, with recent rates nearing $70,000 per day [18][21] - Daily rates for Supramaxes rose from $10,000 to $16,000, and Kamsarmaxes increased from $12,000 to $15,000 during Q3 2025 [11][14] - The dry bulk market experienced a significant upturn in Q3 2025, driven by increased global iron flows and U.S. corn exports [14] Company Strategy and Development Direction - The company aims to expand its fleet to between 25 and 30 ships, supported by a recent capital raise of $60 million [7][22] - The focus remains on enhancing revenue, profits, and asset utilization through fleet expansion and strategic management of high-quality vessels [22] - The company maintains a debt-free balance sheet and a strong cash position, which supports its growth strategy [7][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the tanker and dry bulk markets, noting firming asset values and favorable market conditions [7][12] - The geopolitical landscape, including U.S.-Venezuela tensions and the ongoing effects of the Russia-Ukraine war, could impact future market dynamics [21] - The outlook for Q4 2025 remains positive, with expectations of continued strong rates for both tankers and dry bulk vessels [21][22] Other Important Information - The company ended Q3 2025 with approximately $100 million in cash, a decrease due to the $129 million payment for the acquisition of seven dry bulk vessels [6][20] - A significant dry docking schedule is anticipated for 2026, with 12 vessels needing to be docked [19] Summary of Q&A Session - There was no question-and-answer session at the end of the conference call [2]

2025 R&D Update and ASH Data Review December 11, 2025 © Genmab 2025 This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans ...

Investment in the Company is subject to significant risks and should only be made after a careful review of the relevant documentation and following the consultation of a legal, tax or other adviser. Investing in the Company is speculative, not suitable for all investors, and intended only for investors who are able to bear the high economic risks of such investment, which can include, but are not limited to, loss of all or a substantial portion of your investment. Each prospective purchaser should carefull ...